Docetaxel versus paclitaxel in black patients with breast cancer

The American Society of Clinical Oncology (ASCO) shared a post on X:

“ICYMI from ASCO24:

Although EAZ171 failed to meet its primary endpoint, Black patients with early-stage breast cancer who received docetaxel experienced less TIPN and fewer dose reductions than Black patients who received paclitaxel.”

Additional information.
Source: ASCO/X